Document is current
Any future updates will be listed below
-
Authors
Elsworth, Brendan
Keroack, Caroline D.
Rezvani, Yasaman
Paul, Aditya S. https://orcid.org/0000-0003-4123-7410
Barazorda, Keare A.
Bauer, Niel C.
Tennessen, Jacob A.
Sack, Samantha A.
Moreira, Cristina K.
Gubbels, Marc-Jan https://orcid.org/0000-0002-2769-8600
Meyers, Marvin J. https://orcid.org/0000-0001-5484-619X
Zarringhalam, Kourosh https://orcid.org/0000-0002-5108-8108
Duraisingh, Manoj T. https://orcid.org/0000-0001-8534-5515
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (1R21AI153945, 1R01AI167570-01)
U.S. Department of Health & Human Services | National Institutes of Health (1R21AI150090)
U.S. Department of Health & Human Services | National Institutes of Health (1R21AI150090)
American Heart Association (17POST33410556)
American Heart Association (19PRE34380106)
Department of Health | National Health and Medical Research Council (APP1148392)
- License Information
-
More Information
Article History
Received: 5 February 2023
Accepted: 8 December 2025
First Online: 27 January 2026
Competing interests
: M.T.D., A.S.P. and B.E. are inventors on a pending patent application (US Patent Application Number 63/908,269) around the WM382 compound for babesiosis treatment.
